Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arena Pharmaceuticals (ARNA)

Arena Pharmaceuticals (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arena Pharmaceuticals 136 Heber Avenue Suite 204 Park City UT 84060 USA

P: 858-453-7200

Description:

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.

Key Statistics

Overview:

Market Capitalization, $K 3,669,326
Shares Outstanding, K 61,074
Annual Sales, $ 320 K
Annual Net Income, $ -404,730 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -118,420 K
60-Month Beta 0.49
% of Insider Shareholders 3.05%
% of Institutional Shareholders 91.86%
Float, K 59,211
% Float 96.95%

Growth:

1-Year Return -17.74%
3-Year Return 30.55%
5-Year Return 243.31%
5-Year Revenue Growth -99.17%
5-Year Earnings Growth -64.22%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.40 on 08/05/21
Next Earnings Date N/A
Earnings Per Share ttm -7.38
EPS Growth vs. Prev Qtr -21.21%
EPS Growth vs. Prev Year -49.07%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 06/19/17

ARNA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -16.63
Price/Earnings to Growth N/A
Return-on-Equity % -44.96%
Return-on-Assets % -40.90%
Profit Margin % -126,478.13
Net Margin % -676.30
Debt/Equity 0.04
Price/Sales 11,694.04
Price/Cash Flow N/A
Price/Book 3.79
Book Value/Share 17.89
Interest Coverage -88.54
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar